+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
Healthy Volunteers
ID07231679

Randomized Study of IGT-303 Safety and Pharmacokinetics in Adults with Chronic Kidney Disease and Healthy Volunteers

Led by Ingenia Therapeutics INC · Updated on 2026-10-07

94

Participants Needed

13

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety of IGT-303, a drug given either under the skin or into a vein, in healthy volunteers and people with chronic kidney disease caused by type 2 diabetic nephropathy. The study aims to find out if IGT-303 is safe when given as a single dose or multiple doses compared to a placebo. This is a randomized, double-blind, placebo-controlled clinical trial conducted in multiple centers. Participants will be assigned to receive either IGT-303 or a placebo normal saline through intravenous or subcutaneous administration. The study has two parts Part A involves single ascending doses across six groups, and Part B involves multiple ascending doses across three groups. Researchers will monitor participants closely throughout the study period, which includes dosing and follow-up. During the study, participants will be assessed for adverse events and treatment-emergent events from screening until day 84. Researchers will also collect pharmacokinetic data to understand how the drug behaves in the body over time. Participants may need to stay overnight at the research site and will be monitored for safety and tolerability during this period. The total study duration extends to approximately 84 days of observation after dosing.

CONDITIONS

Brief Title

A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

Research Team

J

Jennifer Curry, PharmD

J

Jinsam You, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here